Table 3.

Maintenance treatment in NSCLC, Disease Control Rate (DCR), Progression Free Survival PFS)

First author/Study	n	Place	Primary Endpoint	Phase	STAGE	MAINTENANCE TREATMENT	Patients
Pallis et al 2007	41	Greece	DCR	II	IIIB/IV	gefitinib as salvage treatment	Pretreated platinum- or taxane-based
Kelly et al 2008 (SWOG S0023)	243	USA	-	III	III	gefitinib or placebo	Pretreated concurrent chemoradiotherapy and docetaxel
Patel et al 2009	50	USA	PFS	II	IIIB/IV nonsquamous	pemetrexed and bevacizumab	Untreated 1st line pemetrexed, carboplatin, and bevacizumab
Zhang et al 2012 (INFORM; C-TONG 0804)	296	China	PFS	III	IIIb or IV	Gefitinib versus placebo	Pretreated 1st-line platinum-based doublet
Cappuzzo et al 2010 (SATURN; BO18192)	884	Italy	PFS	III	advanced	erlotinib	Pretreated 1st line/four cycles of platinum-based chemotherapy